Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Reunion Technology Digest.
Press releases published on September 30, 2025
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (France), September 30, …
Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ®
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie épidémique comme le chikungunya Saint- …
Market-leading Australian investor administration and services platform Automic Group acquired by Advent
Photo Courtesy of Automic Group SYDNEY, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Market-leading Australian investor administration and services platform Automic Group today announced that leading global private equity investor Advent will acquire the business. …
3 E Network Technology Group Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
HONG KONG, Sept. 29, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced that on September …
BIGG Digital Assets Announces Extension of Netcoins Exemptive Relief to Operate a Crypto Trading Platform
VANCOUVER, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQB: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins Inc. (“Netcoins”), Blockchain …
Sapu Nano 的 Sapu003 进入人体临床试验 —— 革新给药方式，实现 Everolimus 全生物利用度，造福乳腺癌患者
Sapu003 旨在克服 Afinitor®（FDA 批准的口服 Everolimus）的局限性，通过静脉注射实现 Everolimus 的全效给药 悉尼澳大利亚, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Deciparticle™ 的开发公司 Sapu Nano 今日宣布，已获澳大利亚人类研究伦理委员会（HREC）批准，启动 Sapu003 的一期人体临床试验患者招募。Sapu003 是一种用于乳腺癌治疗的注射型 Everolimus 制剂。 Sapu Nano 隶属于 …